Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02843074
Title Elotuzumab, Lenalidomide and Dexamethasone (ERd) in the Induction, Consolidation and Maintenance Treatment of Transplant-Eligible, Newly Diagnosed Multiple Myeloma Patients
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors SCRI Development Innovations, LLC
Indications

myeloid neoplasm

Therapies

Dexamethasone + Elotuzumab + Lenalidomide

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.